• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

    19.87 -0.28 (-1.39%)
    Delayed Quote Updated: 12:29 PM EDT, Oct 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about ACADIA Pharmaceuticals Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
    From Acadia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights
    From Halper Sadeh LLC
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.